Clinical Trials Browser

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT04661852 2023-02-15

Cabozantinib With Topotecan-Cyclophosphamide

Phase 1 Completed

12 enrolled

Sarcoma

Sarcoma, Ewing, Osteosarcoma

NCT04173338 2022-06-14

Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma

Phase 1 Terminated

9 enrolled

GenitourinaryOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell

NCT01574937 2021-08-06

XL-184+Abiraterone in Post-Chemo CRPC

Phase 1 Completed

27 enrolled

Genitourinary

Prostatic Neoplasms

NCT02008383 2021-02-12

CaboMAb

Phase 1 Completed

29 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT01663272 2018-09-19

A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer

Phase 1 Completed

12 enrolled 6 charts

Gastrointestinal

Neoplasms, Pancreatic Neoplasms

NCT01961765 2017-07-21

Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1 Completed

18 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT01582295 2017-05-25

XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease

Phase 1 Completed

4 enrolled

Plasma cell

Bone Diseases, Multiple Myeloma

NCT01347788 2016-11-28

Cabozantinib (XL184) in Men With Castrate-Resistant Prostate Cancer

Phase 1 Completed

34 enrolled 6 charts

Genitourinary

Prostatic Neoplasms

Clinical Trials

METTSEO

NF113

CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors

A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the Brain

Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas

Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)

CaboLu

Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study

Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors

Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors

Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC)

Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC)

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Cabozantinib With Topotecan-Cyclophosphamide

Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma

XL-184+Abiraterone in Post-Chemo CRPC

CaboMAb

A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer

Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia

XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease

Cabozantinib (XL184) in Men With Castrate-Resistant Prostate Cancer